Verteporfin

Verteporfin (benzoporphyrin derivative monoacid ring A, BPD-MA, CL 318952) is a semi-synthetic chlorin-class photosensitizer derived from protoporphyrin IX and approved by the United States Food and Drug Administration since April 2000 for the photodynamic therapy of predominantly classic subfoveal choroidal neovascularization secondary to age-related macular degeneration, pathologic myopia, and presumed ocular histoplasmosis syndrome. Marketed as Visudyne by QLT PhotoTherapeutics (subsequently Bausch and Lomb), the compound represented the first pharmacological intervention for neovascular age-related macular degeneration and established ocular photodynamic therapy as a standard of care prior to the introduction of anti-vascular endothelial growth factor agents. The photodynamic mechanism operates through selective accumulation in neovascular endothelium via lipoprotein-mediated uptake, followed by activation with 689 nm non-thermal laser light to generate reactive oxygen species (singlet oxygen and superoxide) that produce localized vascular endothelial damage, thrombosis, and vessel occlusion without thermal injury to the overlying neurosensory retina.

Independent of its photosensitizing activity, verteporfin was identified in 2012 by Liu-Chittenden et al. as a small-molecule inhibitor of the Yes-associated protein (YAP) and transcriptional enhanced associate domain (TEAD) protein-protein interaction, a critical effector node of the Hippo tumor suppressor pathway [1]. This discovery initiated a substantial and expanding preclinical oncology literature demonstrating that verteporfin, without photoactivation, suppresses YAP-driven transcription, inhibits proliferation and invasion, and produces survival benefit in xenograft and orthotopic models of glioblastoma, pancreatic ductal adenocarcinoma, ovarian carcinoma, hepatocellular carcinoma, colorectal carcinoma, melanoma, and retinoblastoma [2, 3, 4, 5]. The YAP-TEAD inhibitory mechanism involves direct binding to YAP that alters its conformation and prevents association with TEAD transcription factors, upregulation of 14-3-3 sigma (stratifin) that sequesters YAP in the cytoplasm, and suppression of downstream targets including connective tissue growth factor (CTGF) and cysteine-rich angiogenic inducer 61 (CYR61) [6, 7].

Pharmacokinetics following the approved intravenous dose of 6 mg per square meter of body surface area are characterized by biexponential disposition with a distribution phase of 1 to 3 hours and a terminal elimination half-life of 5 to 6 hours. Verteporfin is 90 percent associated with plasma lipoproteins (principally low-density lipoprotein) and approximately 6 percent with albumin. Metabolism is limited and occurs through liver and plasma esterases to the diacid metabolite BPD-DA; cytochrome P450 enzymes do not contribute meaningfully to elimination. Excretion is predominantly fecal as unchanged drug, with less than 0.01 percent recovered in urine [8, 9].

This monograph reviews the chemistry, synthesis, and photophysics of verteporfin; the dual mechanism encompassing photodynamic vascular occlusion and light-independent YAP-TEAD inhibition; the comprehensive pharmacokinetic record; the clinical evidence base across ophthalmic and investigational oncologic indications; sourcing and quality verification for research applications; reconstitution and handling protocols; stack-interaction considerations; adverse-event signal including photosensitivity; and a comparative assessment of five alternative photosensitizers or YAP pathway inhibitors against verteporfin on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).